Moderna, Inc. — Director's Dealing 2020

Sep 15, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-09-14

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-09-14	Common Stock	M	10000	$20.93	Acquired	10000	Direct
2020-09-14	Common Stock	M	34	$14.22	Acquired	10034	Direct
2020-09-14	Common Stock	M	10000	$19.15	Acquired	20034	Direct
2020-09-14	Common Stock	S	2082	$60.86	Disposed	17952	Direct
2020-09-14	Common Stock	S	2574	$61.85	Disposed	15378	Direct
2020-09-14	Common Stock	S	10210	$62.79	Disposed	5168	Direct
2020-09-14	Common Stock	S	5168	$63.53	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-09-14	Stock Option (Right to Buy)	$20.93	M	10000	Disposed	2029-03-08	Common Stock (10000)	Direct
2020-09-14	Stock Option (Right to Buy)	$14.22	M	34	Disposed	2028-02-28	Common Stock (34)	Direct
2020-09-14	Stock Option (Right to Buy)	$19.15	M	10000	Disposed	2026-08-10	Common Stock (10000)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.15 to $61.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.23 to $62.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.24 to $63.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.25 to $63.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.

F7: This option is fully vested and exercisable.